Natixis Advisors LLC Acquires 21,384 Shares of Prestige Consumer Healthcare Inc. $PBH

Natixis Advisors LLC grew its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 9.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 237,983 shares of the company’s stock after purchasing an additional 21,384 shares during the quarter. Natixis Advisors LLC’s holdings in Prestige Consumer Healthcare were worth $14,681,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Bayforest Capital Ltd purchased a new position in Prestige Consumer Healthcare during the 4th quarter worth $29,000. Barrow Hanley Mewhinney & Strauss LLC boosted its holdings in Prestige Consumer Healthcare by 106.8% during the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after acquiring an additional 283 shares during the last quarter. Geneos Wealth Management Inc. boosted its holdings in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after acquiring an additional 269 shares during the last quarter. Torren Management LLC purchased a new position in Prestige Consumer Healthcare during the 4th quarter worth $35,000. Finally, Danske Bank A S purchased a new position in Prestige Consumer Healthcare during the 3rd quarter worth $37,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $47.15 on Friday. The company’s 50-day moving average is $53.08 and its 200 day moving average is $59.96. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.25 and a current ratio of 3.57. The company has a market capitalization of $2.23 billion, a P/E ratio of 12.06, a price-to-earnings-growth ratio of 1.52 and a beta of 0.35. Prestige Consumer Healthcare Inc. has a fifty-two week low of $42.62 and a fifty-two week high of $87.12.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The company had revenue of $281.62 million during the quarter, compared to analysts’ expectations of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.Prestige Consumer Healthcare’s quarterly revenue was down 5.0% compared to the same quarter last year. During the same period last year, the firm posted $1.32 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the transaction, the vice president directly owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).